Longevity & Aging
aging is a treatable disease
In plain terms: Is ageing a treatable disease?
Strong support Longevity & Aging
Part of: • Aging
RefutedContestedStrong support
consensus score 1.00
A viewpoint some researchers argue, not a proven fact — and only tested in cells and animals so far.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Population patterns (Observational)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
10 support 0 contradict 0 tested null 0 mixed · 10 sources, 9 independent groups
What the evidence shows
A strategic/regulatory STANCE (geroscience position papers), not an empirical finding. Recorded as a framing claim, deliberately low-weight.
The evidence (15)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Strong R, Miller RA, Antebi A, Astle CM, Bogue M, Denzel MS, Fernandez E, Flurkey K, Hamilton KL, Lamming DW, Javors MA, de Magalhães JP, Martinez PA, McCord JM, Miller BF, Müller M, Nelson JF, Ndukum J, Rainger GE, Richardson A, Sabatini DM, Salmon AB, Simpkins JW, Steegenga WT, Nadon NL, Harrison DE 2016 · Aging Cell | animal | supports | high | NIA ITP: 17-a-estradiol, acarbose, NDGA, Protandim extended mouse lifespan; pharmacologically modifiable aging in mammals (sex/dose dependent) |
| Mohammed I, Hollenberg MD, Ding H, Triggle CR 2021 · Front Endocrinol | observational | mixed | low | Critical review concludes metformin lifespan-extension evidence remains controversial, not protective in disease-free subjects - tempers treatability claim |
| Wissler Gerdes EO, Misra A, Netto JME, Tchkonia T, Kirkland JL 2021 · Mech Ageing Dev | mechanism | supports | moderate | Reviews senolytic trial strategy; reports D+Q reduced senescent-cell burden in diabetic-kidney patients + IPF function gain - target-engagement, not hard outcomes |
| Peng LN, Hsiao FY, Chen LK 2026 · J Chin Med Assoc | observational | supports | moderate | Geromedicine review: WHO ICD-11 MG2A code + FDA-accepted TAME trial framed as institutional milestones for treating aging as multidisease outcome |
| Buch ML, Esser H, Perera H, Zheng R, Ferreira-Gonzalez S, Forbes SJ 2026 · Transpl Int | observational | supports | low | Argues senescence (an aging hallmark) is a modifiable, assessable target in organ transplantation - independent group applying treatability thesis |
| Feltes BC 2026 · (2026 evolutionary-biology review) | observational | contradicts | moderate | Evolutionary/comparative-biology review argues aging is NOT a disease but a conserved, programmed regulatory outcome — a substantive dissent against the treatable-disease framing (argument, not new empirical data). |
| Chen S, Zhang C, Cang P, Guo W, Xiao L, He Y, Su Q, Ouyang S, Zha J, Maimaitirexiati G, Chen Y, Qi X, He S, Zhang Q, Xu Y, Yang J, Fan G 2026 · (2026 multi-omics senolytic study) | animal | supports | moderate | Multi-omics mouse study: dasatinib+quercetin senolytic therapy reduced senescence markers, restored Klotho, and reversed transcriptomic aging signatures in aged kidney — new intervention evidence that an aging process is pharmacologically modifiable (animal). |
| Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK, Pascual R, Hashmi SK, Prata L, Masternak MM, Kritchevsky SB, Musi N, Kirkland JL 2019 · EBioMedicine | observational | supports | low | First-in-human open-label senolytic (D+Q) pilot in IPF improved physical function/mobility - early proof aging mechanism is druggable; n=14 uncontrolled |
| López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G 2023 · Cell | mechanism | supports | high | Twelve hallmarks framework: explicit premise that therapeutic intervention on hallmarks can decelerate/reverse aging - the treatability thesis stated, not proven |
| Xiang Z, Chen Y, Liu X, Lu H, Yang Y, Xing L, Zhang Y, Lang C, Zhang S, Zhao S, Hong Y, Bai J, Qiao Y 2026 · MedComm | mechanism | mixed | low | Narrative review of mitochondria-targeted anti-aging strategies: 'Many mitochondrial drugs that are effective in vitro or animal models face problems of low bioavailability, rapid metabolism, or nonspecific distribution in humans.' No data. Review — zero weight. |
| Kulkarni AS, Aleksic S, Berger DM, Sierra F, Kuchel GA, Barzilai N 2022 · Aging Cell | observational | supports | low | Proposes formal process to repurpose FDA drugs targeting aging biology to delay multiple chronic diseases; advocacy/framework not outcome data |
| Khaltourina D, Matveyev Y, Alekseev A, Cortese F, Ioviţă A 2020 · Mech Ageing Dev | mechanism | supports | low | Khaltourina 2020 ICD-11-criteria argument; framing not empirical |
| Zhavoronkov A, Bhullar B 2015 · Front Genet | observational | mixed | low | Policy perspective, no new data: 'Here, we explore the arguments for classifying aging as a disease in the context of the upcoming World Health Organization’s 11th International Statistical Classification of Diseases and Related Health Problems (ICD-11)' and 'We hypothesize that classifying aging as a disease with a “non-garbage” set of codes will result in new approaches and business models for addressing aging as a treatable condition'. Advocacy/review — zero weight. |
| Bulterijs S, Hull RS, Björk VC, Roy AG 2015 · Front Genet | observational | supports | low | Bulterijs 2015 Frontiers Opinion advocacy/framing not empirical; archived; low-weight correct |
| Rehman A, Satyam SM, El-Tanani M, Prabhakar S, Kumari R, Shetty P, Mohammed SSN, Nafees Z, Alomar B 2025 · Cancers (Basel) | observational | supports | moderate | Metformin reframed as prototype gerotherapeutic; cites TAME/biological-age reversal claims - advocacy review, evidence not from controlled aging endpoint |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.